Caverno-saphenous shunt for recurrent priapism

Area of Science:

• Urology
• Pharmacology
• Surgical Innovation

Background:

• Medication-induced priapism, particularly from injectable erectile dysfunction treatments like Trimix (alprostadil, papaverine, phentolamine), presents a significant clinical challenge.
• Recurrent priapism episodes can lead to treatment refractory states, necessitating advanced therapeutic strategies beyond standard urological algorithms.
• The misuse of erectile dysfunction medications can result in severe, persistent priapism, impacting patient health and requiring specialized interventions.

Observation:

• A patient with a history of medication misuse developed priapism refractory to conventional treatments including phenylephrine, aspiration, and distal shunting.
• Despite initial successful management, continued misuse of injectable erectile dysfunction medication led to treatment failure.
• The refractory nature of the priapism necessitated a rare surgical intervention: a proximal caverno-saphenous bypass.

Findings:

• The caverno-saphenous bypass procedure was successfully performed as a treatment for refractory priapism.
• Following the surgical intervention, the patient experienced preservation of partial sexual function.
• The bypass graft remained patent post-operatively, indicating a successful surgical outcome.

Implications:

• This case highlights the potential for severe priapism due to erectile dysfunction medication misuse.
• Extra-anatomic bypass surgery, such as the caverno-saphenous bypass, represents a viable, albeit rare, option for refractory priapism.
• Effective management strategies for priapism require careful consideration of medication misuse and the potential need for advanced surgical techniques.